New Certificates Of Suitability For Dishman Pharmaceuticals
In the last few months Dishman Pharmaceuticals has successfully obtained the Certificate of suitability to the monographs of the European Pharmacopoeia (CEP) for Indapamide and Bupivacaine HCl.
In the last few months Dishman Pharmaceuticals has successfully obtained the Certificate of suitability to the monographs of the European Pharmacopoeia (CEP) for the following Active Pharmaceutical Ingredients (API):
- Indapamide
- Bupivacaine HCl
The CEP are recognised by the European Union as a single reference work for the quality control of medicines. CEP can be used by the manufacturers of pharmaceutical products in their applications for marketing authorization to demonstrate the compliance of the substance with the monographs of the European Pharmacopoeia. Besides, the official standards published within provide a legal and scientific basis for quality control during the development, production and marketing processes.
Dishman has also recently applied for the CEP for Hexetidine (whose European Drug Master File is currently available). These 3 new certificates complement the current list of Dishman Generic API documentation.
Other “traditional” APIs from Dishman with a CEP are: Tramadol, CPC, Cetrimide Powder, Bisacodyl USP and Benzalkonium Chloride 50%.
To see a full list of Dishman Generic APIs please go to:
www.dishmangroup.com/bulk-api-products.asp
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
